Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012, Int J Cancer, vol.136, issue.5, pp.359-86, 2015. ,
Risk factors and epidemiology of breast cancer, Womens Health Med, vol.3, issue.1, pp.8-14, 2006. ,
Projection de l'incidence et de la mortalité par cancer en France métropolitaine en 2015. Rapport technique. Saint-Maurice : Institut de veille sanitaire ,
The decline in breast cancer mortality in Europe: An update (to 2009). The Breast, vol.21, pp.77-82, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01262966
Advances in Breast Cancer: Pathways to Personalized Medicine, Clin Cancer Res, vol.14, issue.24, pp.7988-99, 2008. ,
Use of molecular markers for predicting therapy response in cancer patients, Cancer Treat Rev, vol.37, issue.2, pp.151-160, 2011. ,
Personalized therapy for breast cancer: a dream or a reality? Future Oncol, vol.9, pp.1105-1124, 2013. ,
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer, J Clin Oncol, vol.27, issue.34, pp.5838-5885, 2009. ,
Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study, 13th St Gallen International Breast Cancer Conference, 2013. ,
Herceptin® (trastuzumab) par voie souscutanée : une mini révolution ? Étude pharmaco-économique, Bull Cancer, vol.102, issue.3, pp.270-276, 2015. ,
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial, Lancet Oncol, vol.13, issue.9, pp.869-78, 2012. ,
Molecular regulators of pubertal mammary gland development, Ann Med, vol.43, issue.3, pp.212-246, 2011. ,
Breast and Ovarian Cancer, N Engl J Med, vol.5, issue.23, pp.2339-2386, 2003. ,
PALB2: research reaching to clinical outcomes for women with breast cancer, Hered Cancer Clin Pract, vol.14, p.9, 2016. ,
Review article: epidemiology of male breast cancer. A metaanalysis of published case-control studies and discussion of selected aetiological factors, Int J Cancer, vol.53, issue.4, pp.538-587, 1993. ,
Unbiased estimates of long-term net survival of solid cancers in France, Int J Cancer, vol.132, issue.10, pp.2370-2377, 2013. ,
La fréquence des cancers en 2016 et leur évolution, Bull Cancer, vol.104, issue.1, pp.20-29, 2017. ,
Histological types of breast cancer: How special are they? Mol Oncol, vol.4, pp.192-208, 2010. ,
Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-52, 2000. ,
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci, vol.98, pp.10869-74, 2001. ,
Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci, vol.8, issue.14, pp.8418-8441, 2003. ,
Recommandations 2013 de la conférence de consensus de Saint-Paul-de-Vence-Traitements néoadjuvants et classification moléculaire ,
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.24, issue.9, pp.2206-2229, 2013. ,
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities, Eur J Cancer, vol.40, issue.18, pp.2667-75, 2004. ,
Clinicopathological classification and individualized treatment of breast cancer, Chin Med J (Engl), vol.126, issue.20, pp.3921-3926, 2013. ,
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer, J Clin Oncol, vol.26, issue.10, pp.1742-51, 2008. ,
Spatial Structure of the Dimeric Transmembrane Domain of the Growth Factor Receptor ErbB2 Presumably Corresponding to the Receptor Active State, J Biol Chem, vol.283, issue.11, pp.6950-6956, 2008. ,
Epidermal growth factor receptor: mechanisms of activation and signalling, Exp Cell Res, vol.284, issue.1, pp.31-53, 2003. ,
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer, EMBO J, vol.15, issue.2, pp.254-64, 1996. ,
The ErbB receptors and their role in cancer progression, Exp Cell Res, vol.284, issue.1, pp.99-110, 2003. ,
The ErbB signaling network: receptor heterodimerization in development and cancer, EMBO J, vol.3, issue.13, pp.3159-67, 2000. ,
Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy, FEBS Lett, vol.584, issue.12, pp.2699-706, 2010. ,
The HER family and cancer: emerging molecular mechanisms and therapeutic targets, Trends Mol Med, vol.13, issue.12, pp.527-561, 2007. ,
évaluation des facteurs pronostiques par immunohistochimie dans les cancers du sein (GEFPICS) ,
HER-2/ neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization, J Clin Oncol, vol.19, issue.2, pp.354-63, 2001. ,
Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization, Hum Pathol, vol.34, issue.10, pp.1043-1050, 2003. ,
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, N Engl J Med, vol.344, issue.11, pp.783-92, 2001. ,
Guide-Affection longue durée. Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique. Cancer du sein, 2010. ,
Breast conservation: evolution of surgical strategies, Breast J, vol.12, issue.5, pp.165-73, 2006. ,
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, vol.11, issue.10, pp.927-960, 2010. ,
The Oncologist, vol.16, pp.800-810, 2011. ,
Recent advances of highly selective CDK4/6 inhibitors in breast cancer, J Hematol OncolJ Hematol Oncol, vol.10, issue.1, 2017. ,
Haute autorité de santé. Commission de la transparence-Avis 25 mai, 2016. ,
Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group, Target Oncol, vol.11, issue.3, pp.277-92, 2016. ,
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues, Expert Opin Biol Ther, vol.8, issue.12, pp.1963-71, 2008. ,
Trastuzumab-Induced Cardiomyopathy, J Card Fail, vol.14, issue.5, pp.437-481, 2008. ,
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience, J Clin Oncol, vol.20, issue.5, pp.1215-1236, 2002. ,
Cardiotoxicity of Trastuzumab in Clinical Practice, N Engl J Med, vol.357, issue.1, pp.94-99, 2007. ,
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. The Breast, vol.20, pp.176-83, 2011. ,
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy, Pharmacol Ther, vol.125, issue.2, pp.196-218, 2010. ,
Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer, Oncology, vol.61, issue.2, pp.58-66, 2001. ,
Grade 3 trastuzumab-induced neutropenia in breast cancer patient, J Oncol Pharm Pract, vol.20, issue.2, pp.154-161, 2014. ,
Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis, Exp Ther Med, 2016. ,
Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer, Eur Respir J, vol.21, issue.3, pp.552-557, 2003. ,
Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer, Immunotherapy, vol.6, issue.7, pp.811-820, 2014. ,
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration, AAPS J, vol.17, issue.5, pp.1144-56, 2015. ,
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer: The Journal of Clinical Pharmacology, J Clin Pharmacol, vol.53, issue.2, pp.192-201, 2013. ,
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study, Ann Oncol, vol.26, issue.2, pp.320-325, 2015. ,
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up, Eur J Cancer, vol.62, pp.62-75, 2016. ,
Satisfaction des patientes traitées par chimiothérapie en hôpital de jour pour un cancer du sein : résultats de l'enquête TemporELLES, Bull Cancer, vol.102, issue.4, pp.316-339, 2015. ,
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study, Ann Oncol, vol.25, issue.10, pp.1979-87, 2014. ,
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study, Lancet Oncol, vol.14, issue.10, pp.962-70, 2013. ,
Les individus face à l'événement « cancer, Temporalités. 2011. *En ligne+. Disponible sur ,
Mission sous-cutanée à l'Institut Bergonié. Le bulletin infirmier du cancer, vol.15, 2015. ,
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. The Breast, vol.34, pp.89-95, 2017. ,
Administration Reactions in Women with Breast Cancer Receiving Subcutaneous Trastuzumab, Clinical Oncology, vol.5, issue.28, p.4, 2016. ,
Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm, vol.58, issue.18, pp.1760-1764, 2001. ,